Comparing different domains of analysis for the characterisation of N-glycans on monoclonal antibodies
- Author:
Carillo SARA
1
;
Pérez-Robles RAQUEL
;
Jakes CRAIG
;
Meire Ribeiro da Silva
;
Martín Millán SILVIA
;
Farrell AMY
;
Navas NATALIA
;
Bones JONATHAN
Author Information
1. Characterisation and Comparability Laboratory
- Keywords:
N-Glycans;
Biopharmaceuticals;
Monoclonal antibodies;
Intact mass analysis;
Mass spectrometry;
Native mass spectrometry;
Glycan analysis;
Peptide mapping;
Glycopeptide analysis
- From:
Journal of Pharmaceutical Analysis
2020;10(1):23-34
- CountryChina
- Language:Chinese
-
Abstract:
With the size of the biopharmaceutical market exponentially increasing, there is an aligned growth in the importance of data-rich analyses, not only to assess drug product safety but also to assist drug development driven by the deeper understanding of structure/function relationships. In monoclonal antibodies, many functions are regulated by N-glycans present in the constant region of the heavy chains and their mechanisms of action are not completely known. The importance of their function focuses analytical research efforts on the development of robust, accurate and fast methods to support drug development and quality control. Released N-glycan analysis is considered as the gold standard for glycosylation characterisation;however, it is not the only method for quantitative analysis of glycoform heterogeneity. In this study, ten different analytical workflows for N-glycan analysis were compared using four monoclonal antibodies. While observing good comparability between the quantitative results generated, it was possible to appreciate the advantages and disadvantages of each technique and to summarise all the observations to guide the choice of the most appropriate analytical workflow ac-cording to application and the desired depth of data generated.
